Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Clinicum, Department of Public Health, University of Helsinki, Helsinki, Finland; Department of Epidemiology and Public Health, University College London, London, UK; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Am J Hum Genet. 2022 Dec 1;109(12):2152-2162. doi: 10.1016/j.ajhg.2022.10.009. Epub 2022 Nov 7.
Family history is the standard indirect measure of inherited susceptibility in clinical care, whereas polygenic risk scores (PRSs) have more recently demonstrated potential for more directly capturing genetic risk in many diseases. Few studies have systematically compared how these overlap and complement each other across common diseases. Within FinnGen (N = 306,418), we leverage family relationships, up to 50 years of nationwide registries, and genome-wide genotyping to examine the interplay of family history and genome-wide PRSs. We explore the dynamic for three types of family history across 24 common diseases: first- and second-degree family history and parental causes of death. Covering a large proportion of the burden of non-communicable diseases in adults, we show that family history and PRS are independent and not interchangeable measures, but instead provide complementary information on inherited disease susceptibility. The PRSs explained on average 10% of the effect of first-degree family history, and first-degree family history 3% of PRSs, and PRS effects were independent of both early- and late-onset family history. The PRS stratified the risk similarly in individuals with and without family history. In most diseases, including coronary artery disease, glaucoma, and type 2 diabetes, a positive family history with a high PRS was associated with a considerably elevated risk, whereas a low PRS compensated completely for the risk implied by positive family history. This study provides a catalogue of risk estimates for both family history of disease and PRSs and highlights opportunities for a more comprehensive way of assessing inherited disease risk across common diseases.
家族史是临床护理中遗传性易感性的标准间接衡量标准,而多基因风险评分(PRS)最近在许多疾病中更直接地捕捉遗传风险方面显示出了潜力。很少有研究系统地比较了这些在常见疾病中如何相互重叠和补充。在 FinnGen 中(N=306418),我们利用家族关系、长达 50 年的全国性登记和全基因组基因分型,研究家族史和全基因组 PRS 之间的相互作用。我们探讨了 24 种常见疾病中三种类型家族史的动态:一级和二级家族史以及父母死因。涵盖了成年人中大部分非传染性疾病的负担,我们表明家族史和 PRS 是独立的且不可互换的衡量标准,而是提供了关于遗传性疾病易感性的互补信息。PRS 平均解释了一级家族史影响的 10%,一级家族史解释了 PRS 的 3%,并且 PRS 效应独立于早发和晚发家族史。PRS 以相似的方式对有家族史和无家族史个体的风险进行分层。在大多数疾病中,包括冠状动脉疾病、青光眼和 2 型糖尿病,具有高 PRS 的阳性家族史与风险显著升高相关,而低 PRS 则完全补偿了阳性家族史所暗示的风险。本研究提供了疾病家族史和 PRS 的风险估计目录,并强调了在常见疾病中更全面地评估遗传疾病风险的机会。